CD274 and neoplasm: The CheckMate 066 study conducted by Robert et al to determine whether nivolumab, as compared with dacarbazine, improves overall survival among previously untreated advanced melanoma patients, demonstrated a survival benefit with nivolumab regardless of tumor cells PD-L1 expression status.